Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
View Patent ↗The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.
1. A method of vaccinating a subject against smallpox, wherein the method comprises
administering to the subject in need of smallpox vaccination a recombinant vaccinia virus having integrated into its viral genome an exogenous sequence encoding a prodrug converting polypeptide under transcriptional control of a poxvirus regulatory region, wherein said prodrug converting polypeptide can convert a prodrug into a drug that inhibits vaccinia virus replication.
2. The method according to claim 1 , wherein the vaccinia virus is a smallpox vaccine strain selected from the group of strains consisting of Lister/Elstree, New York City Board of Health, Temple of Heaven and LC16 m2.
3. The method according to claim 1 , wherein the exogenous sequence is integrated into a non-essential region of the viral genome.
4. The method according to claim 1 , wherein the non-essential region is an intergenic region.
5. The method according to claim 1 , wherein the prodrug converting polypeptide is a thymidine kinase from herpes simplex virus or cytomegalovirus.
6. The method according to claim 1 , wherein said prodrug converting polypeptide is a fusion protein.
7. The method according to claim 6 , wherein the fusion protein is E.coli thymidine kinase/thymidylate kinase (tk/tmk).
8. The method according to claim 1 , wherein the prodrug is a nucleoside analog.
9. The method according to claim 1 , wherein the prodrug is selected from the group consisting of 3′azido-2′,3′-dideoxythymidine (AZT), gancyclovir (GCV) and acyclovir (ACV).
10. A method to treat a vaccinated subject showing signs of vaccination-induced disease after needed vaccination with a smallpox vaccine comprising recombinant vaccinia virus having integrated into its viral genome an exogenous sequence encoding a prodrug converting polypeptide under transcriptional control of a poxvirus regulatory region, wherein the method comprises the step of
administering to the vaccinated subject a prodrug in an effective dose for a time sufficient to at least reduce the titer of recombinant vaccinia virus, wherein the prodrug is converted by the prodrug converting polypeptide to a drug that inhibits viral replication.
11. The method according to claim 10 , wherein the prodrug is selected from the group consisting of 3′azido-2′,3′-dideoxythymidine (AZT), gancyclovir (GCV) and acyclovir (ACV).
12. The method according to claim 10 , wherein the inhibition of replication of vaccinia is monitored by determination of viral load of the organism.
13. The method according to claim 10 , whereby the prodrug is given orally, intravenously or topically.
14. The method of claim 10 , further comprising administering an anti-vaccinia immune globulin to the vaccinated subject.